Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Director/PDMR Shareholding - Replacement

June 22, 2021
RNS Number : 7366C Renalytix AI PLC 22 June 2021   The following amendment(s) has been made to the ' Director/PDMR Dealing ' announcement released on 22 June 2021 at 10:57 under RNS No 7062C.   The price of 113.5 pence per share was incorrect and has been amended to 1135 pence per share.

Director/PDMR Shareholding

June 22, 2021
RNS Number : 7062C Renalytix AI PLC 22 June 2021   Renalytix AI plc    ("Renalytix" or the "Company") Director/PDMR Dealing The Company was informed that today, Christopher Mills , a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each

Financial Results for Third Quarter of FY 2021

June 15, 2021
RNS Number : 9139B Renalytix AI PLC 15 June 2021   Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021   NEW YORK , June 15, 2021   - Renalytix AI plc   (LSE : RENX) (NASDAQ: RNLX) ("Renalytix" or the "Company") today reported financial results for the quarter and nine months

Notice of Results & Change of Auditor

June 10, 2021
RNS Number : 4033B Renalytix AI PLC 10 June 2021   Renalytix AI plc (" Renalytix " or the " Company ")   Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update   Announces Change of Auditor to Ernst & Young LLP   NEW YORK ,  June 10, 2021   - Renalytix AI

Key new hires to drive commercialization strategy

June 7, 2021
RNS Number : 9511A Renalytix AI PLC 07 June 2021     Renalytix AI plc (" Renalytix " or the " Company ")   Leadership additions announced to support expanding US Government and Healthcare Provider KidneyIntelX Deployment   Enabling expertise in sales, population health and value-driven care models

Utility Study

June 3, 2021
RNS Number : 6483A Renalytix AI PLC 03 June 2021   Renalytix AI plc   (" Renalytix " or the " Company ")     Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care   Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment

Director/PDMR Shareholding

May 25, 2021
RNS Number : 7052Z Renalytix AI PLC 25 May 2021   Renalytix AI plc     ("Renalytix" or the "Company")   Director/PDMR Dealing   New York , 25 May 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by James McCullough , the Company's Chief Executive Officer, of 10,462

Director/PDMR Dealing

May 21, 2021
RNS Number : 4140Z Renalytix AI PLC 21 May 2021   Renalytix AI plc     ("Renalytix" or the "Company")    Director/PDMR Dealing   New York , 21 May 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by James McCullough , the Company's Chief Executive Officer, of 54,538

Partnership

May 19, 2021
RNS Number : 1113Z Renalytix AI PLC 19 May 2021   Renalytix AI plc   (" RenalytixAI " or the " Company ")     ATRIUM HEALTH, WAKE FOREST BAPTIST HEALTH, WAKE FOREST SCHOOL OF MEDICINE  AND RENALYTIX PARTNER TO ADVANCE KIDNEY HEALTH   Partnership marks a long-term commitment to reducing impact of

Second Price Monitoring Extn

April 22, 2021
RNS Number : 3487W Renalytix AI PLC 22 April 2021   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
Displaying 71 - 80 of 205